Literature DB >> 21125294

Immunization against leishmaniasis by PLGA nanospheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN.

Mohsen Tafaghodi1, Ali Khamesipour, Mahmoud R Jaafari.   

Abstract

Various adjuvants and delivery systems have been evaluated for increasing the protective immune responses against leishmaniasis and mostly have been shown not to be effective enough. In this study, poly(D,L-lactide-co-glycolide) (PLGA) nanospheres as an antigen delivery system and CpG-ODN as an immunoadjuvant have been used for the first time to enhance the immune response against autoclaved Leishmania major (ALM). PLGA nanospheres were prepared by a double-emulsion (W/O/W) technique. Particulate characteristics were studied by scanning electron microscopy and particle size analysis. Mean diameter of ALM + CpG-ODN-loaded nanospheres was 300 ± 128 nm. BALB/c mice were immunized three times in 3-week intervals using ALM plus CpG-ODN-loaded nanospheres [(ALM + CpG-ODN)(PLGA)], ALM encapsulated PLGA nanospheres [(ALM)(PLGA)], (ALM)(PLGA) + CpG, ALM + CpG, ALM alone, or phosphate buffer solution (PBS). The intensity of infection induced by L. major challenge was assessed by measuring size of footpad swelling. The strongest protection, showed by significantly (P<0.05) smaller footpad, was observed in mice immunized with (ALM + CpG-ODN)(PLGA). The (ALM)(PLGA), (ALM)(PLGA) + CpG, and ALM + CpG were also showed a significantly (P<0.05) smaller footpad swelling compared to the groups received either PBS or ALM alone. The mice immunized with (ALM + CpG-ODN)(PLGA), (ALM)(PLGA) + CpG, and ALM + CpG showed the highest IgG2a/IgG1 ratio, interferon-γ production, and lowest interleukin-4 production compared to the other groups. It is concluded that when both PLGA nanospheres and CpG-ODN adjuvants were used simultaneously, it induce stronger immune response and enhance protection rate against Leishmania infection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21125294     DOI: 10.1007/s00436-010-2176-4

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  52 in total

1.  A Toll-like receptor recognizes bacterial DNA.

Authors:  H Hemmi; O Takeuchi; T Kawai; T Kaisho; S Sato; H Sanjo; M Matsumoto; K Hoshino; H Wagner; K Takeda; S Akira
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

2.  Evaluation of the clearance characteristics of various microspheres in the human nose by gamma-scintigraphy.

Authors:  Mohsen Tafaghodi; S Abolghasem Sajadi Tabassi; Mahmood-Reza Jaafari; S Rasoul Zakavi; Mahdi Momen-Nejad
Journal:  Int J Pharm       Date:  2004-08-06       Impact factor: 5.875

3.  Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis.

Authors:  R X Armijos; M M Weigel; M Calvopina; A Hidalgo; W Cevallos; J Correa
Journal:  Vaccine       Date:  2004-03-12       Impact factor: 3.641

4.  Immune responses to an inactive vaccine against American cutaneous leishmaniasis together with granulocyte-macrophage colony-stimulating factor.

Authors:  Ivonise Follador; Cibele Araujo; Glória Orge; Lay Har Cheng; Lucas P de Carvalho; Olívia Bacellar; Roque P Almeida; Edgar M Carvalho
Journal:  Vaccine       Date:  2002-01-31       Impact factor: 3.641

5.  Epidemiology of cutaneous leishmaniasis in Iran: B. Khorassan Part V: Report on a focus of zoonotic cutaneous leishmaniasis in Esferayen.

Authors:  E Javadian; A Nadim; G Tahvildare-Bidruni; V Assefi
Journal:  Bull Soc Pathol Exot Filiales       Date:  1976 Mar-Apr

Review 6.  The regulation of immunity to Leishmania major.

Authors:  S L Reiner; R M Locksley
Journal:  Annu Rev Immunol       Date:  1995       Impact factor: 28.527

7.  Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durability.

Authors:  Susana Mendez; Khaled Tabbara; Yasmine Belkaid; Sylvie Bertholet; Daniela Verthelyi; Dennis Klinman; Robert A Seder; David L Sacks
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

8.  Alum-precipitated autoclaved Leishmania major plus bacille Calmette-Guérrin, a candidate vaccine for visceral leishmaniasis: safety, skin-delayed type hypersensitivity response and dose finding in healthy volunteers.

Authors:  A A Kamil; E A G Khalil; A M Musa; F Modabber; M M Mukhtar; M E Ibrahim; E E Zijlstra; D Sacks; P G Smith; F Zicker; A M El-Hassan
Journal:  Trans R Soc Trop Med Hyg       Date:  2003 May-Jun       Impact factor: 2.184

9.  Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments.

Authors:  Parviz Ahmad-Nejad; Hans Häcker; Mark Rutz; Stefan Bauer; Ramunas M Vabulas; Hermann Wagner
Journal:  Eur J Immunol       Date:  2002-07       Impact factor: 5.532

Review 10.  First generation leishmaniasis vaccines: a review of field efficacy trials.

Authors:  Sassan Noazin; Farrokh Modabber; Ali Khamesipour; Peter G Smith; Lawrence H Moulton; Kiumarss Nasseri; Iraj Sharifi; Eltahir A G Khalil; Ivan Dario Velez Bernal; Carlos M F Antunes; Marie Paule Kieny; Marcel Tanner
Journal:  Vaccine       Date:  2008-10-23       Impact factor: 3.641

View more
  15 in total

Review 1.  Peptide/protein vaccine delivery system based on PLGA particles.

Authors:  Mojgan Allahyari; Elham Mohit
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

2.  Advances in Integrative Nanomedicine for Improving Infectious Disease Treatment in Public Health.

Authors:  Iris R Bell; Gary E Schwartz; Nancy N Boyer; Mary Koithan; Audrey J Brooks
Journal:  Eur J Integr Med       Date:  2013-04-01       Impact factor: 1.314

3.  The effect of verapamil on in vitro susceptibility of promastigote and amastigote stages of Leishmania tropica to meglumine antimoniate.

Authors:  Azar Shokri; Iraj Sharifi; Ali Khamesipour; Nozar Nakhaee; Majid Fasihi Harandi; Jafar Nosratabadi; Maryam Hakimi Parizi; Mohammad Barati
Journal:  Parasitol Res       Date:  2011-08-17       Impact factor: 2.289

4.  Cationic liposomes containing soluble Leishmania antigens (SLA) plus CpG ODNs induce protection against murine model of leishmaniasis.

Authors:  Vahid Heravi Shargh; Mahmoud Reza Jaafari; Ali Khamesipour; Seyed Amir Jalali; Hengameh Firouzmand; Azam Abbasi; Ali Badiee
Journal:  Parasitol Res       Date:  2012-01-06       Impact factor: 2.289

5.  Preparation, characterization, and insecticidal activity evaluation of three different formulations of Beauveria bassiana against Musca domestica.

Authors:  Sapna Mishra; Peeyush Kumar; Anushree Malik
Journal:  Parasitol Res       Date:  2013-07-17       Impact factor: 2.289

Review 6.  Recent progress concerning CpG DNA and its use as a vaccine adjuvant.

Authors:  Hidekazu Shirota; Dennis M Klinman
Journal:  Expert Rev Vaccines       Date:  2013-11-26       Impact factor: 5.217

Review 7.  Emerging therapeutic targets for treatment of leishmaniasis.

Authors:  Shyam Sundar; Bhawana Singh
Journal:  Expert Opin Ther Targets       Date:  2018-05-09       Impact factor: 6.902

8.  Evaluation of the adjuvant effect of pidotimod on the immune protection induced by UV-attenuated Toxoplasma gondii in mouse models.

Authors:  Ying Zhao; Bo Huang; Shiguang Huang; Huanqin Zheng; Yun-quan Li; Zhao-rong Lun; Jilong Shen; Yong Wang; Lloyd H Kasper; Fangli Lu
Journal:  Parasitol Res       Date:  2013-06-20       Impact factor: 2.289

9.  Towards development of novel immunization strategies against leishmaniasis using PLGA nanoparticles loaded with kinetoplastid membrane protein-11.

Authors:  Diego M Santos; Marcia W Carneiro; Tatiana R de Moura; Kiyoshi Fukutani; Jorge Clarencio; Manuel Soto; Socorro Espuelas; Claudia Brodskyn; Aldina Barral; Manoel Barral-Netto; Camila I de Oliveira
Journal:  Int J Nanomedicine       Date:  2012-04-24

10.  Adjuvants for Leishmania vaccines: from models to clinical application.

Authors:  Vanitha S Raman; Malcolm S Duthie; Christopher B Fox; Greg Matlashewski; Steven G Reed
Journal:  Front Immunol       Date:  2012-06-11       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.